Effect of Testosterone on Natriuretic Peptide Levels.
Administration, Topical
Adult
Anastrozole
/ pharmacology
Androgens
/ administration & dosage
Antineoplastic Agents, Hormonal
/ pharmacology
Aromatase Inhibitors
/ pharmacology
Correlation of Data
Drug Monitoring
/ methods
Estradiol
/ metabolism
Goserelin
/ pharmacology
Healthy Volunteers
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Testosterone
/ administration & dosage
BNP
NT-proBNP
cardiovascular risk
hypertension
natriuretic peptide
testosterone
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
26 03 2019
26 03 2019
Historique:
received:
09
07
2018
revised:
15
11
2018
accepted:
10
12
2018
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
28
2
2020
Statut:
ppublish
Résumé
Circulating natriuretic peptide (NP) levels are markedly lower in healthy men than women. A relative NP deficiency in men could contribute to their higher risk of hypertension and cardiovascular disease. Epidemiological studies suggest testosterone may contribute to sex-specific NP differences. This study aimed to determine the effect of testosterone administration on NP levels using a randomized, placebo-controlled design. One hundred and fifty-one healthy men (20 to 50 years of age) received goserelin acetate to suppress endogenous production of gonadal steroids, and anastrazole to suppress conversion of testosterone to estradiol. Subjects were randomized to placebo gel or 4 different doses of testosterone (1%) gel for 12 weeks. Serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testosterone levels were measured at baseline and follow-up. Men who did not receive testosterone replacement (placebo gel group) after suppression of endogenous gonadal steroid production experienced a profound decrease in serum testosterone (median 540 to 36 ng/dl; p < 0.0001). This was accompanied by an increase in median NT-proBNP (+8 pg/ml; p = 0.02). Each 1-g increase in testosterone dose was associated with a 4.3% lower NT-proBNP at follow-up (95% confidence interval: -7.9% to -0.45%; p = 0.029). An individual whose serum testosterone decreased by 500 ng/dl had a 26% higher predicted follow-up NT-proBNP than someone whose serum testosterone remained constant. Suppression of testosterone production in men led to increases in circulating NT-proBNP, which were attenuated by testosterone replacement. Inhibition of NP production by testosterone may partly explain the lower NP levels in men. (Dose-Response of Gonadal Steroids and Bone Turnover in Men; NCT00114114).
Sections du résumé
BACKGROUND
Circulating natriuretic peptide (NP) levels are markedly lower in healthy men than women. A relative NP deficiency in men could contribute to their higher risk of hypertension and cardiovascular disease. Epidemiological studies suggest testosterone may contribute to sex-specific NP differences.
OBJECTIVES
This study aimed to determine the effect of testosterone administration on NP levels using a randomized, placebo-controlled design.
METHODS
One hundred and fifty-one healthy men (20 to 50 years of age) received goserelin acetate to suppress endogenous production of gonadal steroids, and anastrazole to suppress conversion of testosterone to estradiol. Subjects were randomized to placebo gel or 4 different doses of testosterone (1%) gel for 12 weeks. Serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testosterone levels were measured at baseline and follow-up.
RESULTS
Men who did not receive testosterone replacement (placebo gel group) after suppression of endogenous gonadal steroid production experienced a profound decrease in serum testosterone (median 540 to 36 ng/dl; p < 0.0001). This was accompanied by an increase in median NT-proBNP (+8 pg/ml; p = 0.02). Each 1-g increase in testosterone dose was associated with a 4.3% lower NT-proBNP at follow-up (95% confidence interval: -7.9% to -0.45%; p = 0.029). An individual whose serum testosterone decreased by 500 ng/dl had a 26% higher predicted follow-up NT-proBNP than someone whose serum testosterone remained constant.
CONCLUSIONS
Suppression of testosterone production in men led to increases in circulating NT-proBNP, which were attenuated by testosterone replacement. Inhibition of NP production by testosterone may partly explain the lower NP levels in men. (Dose-Response of Gonadal Steroids and Bone Turnover in Men; NCT00114114).
Identifiants
pubmed: 30898204
pii: S0735-1097(19)30287-6
doi: 10.1016/j.jacc.2018.12.062
pmc: PMC6588352
mid: NIHMS1522183
pii:
doi:
Substances chimiques
Androgens
0
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Goserelin
0F65R8P09N
Natriuretic Peptide, Brain
114471-18-0
Anastrozole
2Z07MYW1AZ
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
Banques de données
ClinicalTrials.gov
['NCT00114114']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1288-1296Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007061
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL092902
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007028
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK002759
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK113220
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR001066
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG030545
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025758
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL102780
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL128928
Pays : United States
Organisme : CSRD VA
ID : IK2 CX001678
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.
Références
Am J Cardiol. 2002 Aug 1;90(3):254-8
pubmed: 12127613
Nat Genet. 2009 Mar;41(3):348-53
pubmed: 19219041
Clin Chem. 2006 May;52(5):827-31
pubmed: 16543387
Horm Metab Res. 2014 Feb;46(2):116-9
pubmed: 24062090
Cardiovasc Res. 1996 Jan;31(1):7-18
pubmed: 8849584
JAMA. 2009 Jul 8;302(2):168-78
pubmed: 19584346
Life Sci. 1993;53(9):689-96
pubmed: 8355570
Life Sci. 1993;52(2):205-12
pubmed: 8355561
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4239-44
pubmed: 10737768
Horm Metab Res. 1999 Sep;31(9):487-98
pubmed: 10569249
Fertil Steril. 2012 Feb;97(2):489-93
pubmed: 22137497
N Engl J Med. 2013 Sep 12;369(11):1011-22
pubmed: 24024838
N Engl J Med. 1998 Jul 30;339(5):321-8
pubmed: 9682046
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4304-4314
pubmed: 30137406
J Am Heart Assoc. 2015 May 21;4(5):
pubmed: 25999400
J Clin Invest. 2016 Mar 1;126(3):1114-25
pubmed: 26901812
J Am Coll Cardiol. 2002 Sep 4;40(5):976-82
pubmed: 12225726
J Am Coll Cardiol. 2011 Aug 2;58(6):618-26
pubmed: 21798425
Circulation. 1998 Jul 21;98(3):256-61
pubmed: 9697826
J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
pubmed: 11158037
Circulation. 2017 Feb 7;135(6):544-555
pubmed: 28153991
Biol Chem Hoppe Seyler. 1992 Apr;373(4):213-8
pubmed: 1534483
Hum Reprod. 2007 Nov;22(11):2992-8
pubmed: 17855407
JACC Heart Fail. 2015 Jul;3(7):513-519
pubmed: 26071618
Prev Sci. 2001 Mar;2(1):15-28
pubmed: 11519372
Clin Chim Acta. 2010 Feb;411(3-4):280-4
pubmed: 19945451
Clin Endocrinol (Oxf). 2016 Jan;84(1):55-62
pubmed: 26120052
J Card Fail. 2005 Jun;11(5 Suppl):S81-3
pubmed: 15948107
Psychol Methods. 2002 Dec;7(4):422-45
pubmed: 12530702
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
Circulation. 2004 Feb 10;109(5):594-600
pubmed: 14769680